Evidence map›Paper›PMID 42012189›Full record

ArticleProteins2026

The Mycobacterium tuberculosis Rv0132c Gene Product Mtb-FGD2 Can Act as an F

Adewale V Aderemi, Matthew Snee, Richard B Tunnicliffe, Linus O Johanissen, Matthew J Cliff, Colin W Levy, Derren J Heyes, Marina Golovanova, Thomas A Jowitt, Sam Hay and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Adewale V AderemiManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Matthew SneeManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Richard B TunnicliffeBiomolecular Analysis Core Facility, Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Manchester, UK.
Linus O JohanissenManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Matthew J CliffManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Colin W LevyManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Derren J HeyesManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Marina GolovanovaManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Thomas A JowittSchool of Biological Sciences, Faculty of Biology, Medicine and Health, Michael Smith Building, University of Manchester, Manchester, UK.
Sam HayManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Andrew W MunroManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
Jonathan P WalthoManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.
David LeysManchester Institute of Biotechnology, Department of Chemistry, University of Manchester, Manchester, UK.

Funding

Biotechnology and Biological Sciences Research Council BB/I019227/1Biotechnology and Biological Sciences Research Council BB/R009961/1Biotechnology and Biological Sciences Research Council BB/X019217/1Tertiary Education Trust Fund
6 · The paper itself

Abstract

The role of the cell envelope-associated Rv0132c/FGD2 from Mycobacterium tuberculosis has long been a subject of debate. Importantly, FGD2 is found only in pathogenic mycobacteria, making it a potential drug target. While some suggest it functions as a glucose-6-phosphate dehydrogenase, others propose it acts instead as an F

Indexed as

Bacterial ProteinsGlucose 1-DehydrogenaseMycobacterium tuberculosisCatalytic DomainCell WallCrystallography, X-RayEscherichia coliGlucoseMolecular Docking SimulationMolecular Dynamics SimulationMycolic AcidsProtein BindingRecombinant ProteinsRiboflavinSubstrate SpecificityBacterial Proteinscoenzyme F420GlucoseGlucose 1-DehydrogenaseMycolic AcidsRecombinant ProteinsRiboflavinF420glucose dehydrogenaseMycobacterium tuberculosisredox enzymeRv0132c

Identifiers

PMID42012189
PMCPMC13434993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.